Montes-Moreno et al., 2012 - Google Patents

EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB …

Montes-Moreno et al., 2012

View HTML
Document ID
17034597522171852995
Author
Montes-Moreno S
Odqvist L
Diaz-Perez J
Lopez A
De Villambrosía S
Mazorra F
Castillo M
Lopez M
Pajares R
García J
Mollejo M
Camacho F
Ruiz-Marcellán C
Adrados M
Ortiz N
Franco R
Ortiz-Hidalgo C
Suarez-Gauthier A
Young K
Piris M
Publication year
Publication venue
Modern Pathology

External Links

Snippet

Here, we report a retrospective series of 47 EBV-positive diffuse large B-cell lymphoma associated with advanced age. Histopathology allowed to the identification of different histological patterns: cases with polymorphic diffuse large B-cell lymphoma (29 cases) …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Montes-Moreno et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation
Cho Basic immunohistochemistry for lymphoma diagnosis
Campo et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Chadburn et al. HHV8/KSHV-positive lymphoproliferative disorders and the spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP workshop report—part 3
Saito et al. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications
Griffin et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM
Four et al. PD 1 and PDL 1 expression in primary central nervous system diffuse large B‐cell lymphoma are frequent and expression of PD 1 predicts poor survival
Campo et al. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece
Boyd et al. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results
Fang et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
Hecking et al. Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
Pannone et al. The role of EBV in the pathogenesis of Burkitt’s Lymphoma: an Italian hospital based survey
Hoeller et al. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study
Mackrides et al. Epstein-Barr virus-positive follicular lymphoma
Feldman et al. PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus
Fend et al. Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. meeting of the European Association of Hematopathology and the Society of Hematopathology in Uppsala, Sweden
Enblad et al. Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population
KR20140100580A (en) Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject
Bienemann et al. High incidence of Epstein–Barr virus (EBV)‐positive Hodgkin lymphoma and Hodgkin lymphoma‐like B‐cell lymphoproliferations with EBV latency profile 2 in children with interleukin‐2‐inducible T‐cell kinase deficiency
Nakajima et al. Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non‐alcoholic fatty liver disease: comparison with telomere‐specific quantitative FISH and p21 immunohistochemistry
Dinu et al. NET G3 vs NEC: p53 and Rb1 immunolabeling in high-grade gastrointestinal neuroendocrine neoplasms-is it enough for the differential diagnosis?
Matsuda et al. Significance of p53‐binding protein 1 nuclear foci in uterine cervical lesions: endogenous DNA double strand breaks and genomic instability during carcinogenesis
Saikia et al. Analysis of Epstein Barr virus encoded RNA expression in nasopharyngeal carcinoma in north-eastern India: a chromogenic in situ hybridization based study
Kinoshita et al. Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
KR20230170982A (en) Methods for Enriching Cells or Cell Nuclei